OKYO Pharma Ltd. has released its annual report for the fiscal year ending March 31, 2025. The company reported that it has not generated any revenue from product sales to date and does not anticipate generating such revenue in the near future. This is due to the ongoing development efforts for their product candidates, which have not yet resulted in regulatory approval. The report outlines that OKYO Pharma Ltd. continues to focus on research and development, which is reflected in their operating expenses. The company has not provided specific figures for net income or profit/loss, as their efforts remain in the developmental stage with no revenue generation from product sales. There is no specific guidance or outlook provided in the report regarding future earnings per share or revenue expectations. The company's strategy remains centered on advancing their product candidates through development and eventual regulatory approval to achieve future revenue generation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.